Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

Fig. 2

Oral intake of empagliflozin prevents heart remodeling in ZSF1 rats. ad All the four cavities of heart (left ventricle and septum, right ventricle, left auricle and septum and right auricle) were weighted and indexed to the respective tibial length. ej The different cardiac markers related to cardiac function and morphology were assessed by echocardiography. Values are shown as mean ± SEM of n = 6–10 per group. *P < 0.05 vs control group and #P < 0.05 vs ZSF1 group

Back to article page